Simon X. Benito - 20 May 2026 Form 4 Insider Report for INOVIO PHARMACEUTICALS, INC. (INO)

Reporting relationship: Director
Issuer ticker: INO
Reported as of: 20 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 May 2026, 16:06:21 UTC
Prior SEC filing: 21 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Simon X. Benito

Key filing fact

Simon X. Benito filed Form 4 for INOVIO PHARMACEUTICALS, INC. (INO) on 21 May 2026.

Key facts

This page summarizes Simon X. Benito's Form 4 filing for INOVIO PHARMACEUTICALS, INC. (INO).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 21 May 2026, 16:06.

Change

Previous filing in this sequence was filed on 21 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001273306 Primary reporting owner

BENITO SIMON X

Relationship: Director
Address: 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING
Signature: /s/ Simon X. Benito
Signature date: 21 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INO transaction Derivative

Common Stock Options

Award

Transaction value
Shares: +41,800
Change %
Price: $0.000000^*
Shares after: 41,800
Date: 20 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 41,800
Exercise price: $1.23
Footnotes: F1, F2

INO transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares: +34,200
Change %
Price: $0.000000^*
Shares after: 34,200
Date: 20 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 34,200
Exercise price
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy.

Footnote F2

Options to vest 100% on May 20, 2027.

Footnote F3

Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027.